As a matter of fact, among patients chronically treated with cabergoline for PRL-secreting tumours, impaired cardiometabolic parameters were found exclusively in patients displaying hypoprolactinemia as compared to those achieving normoprolactinemia or cabergoline-naïve [73, 74], and PRL levels have been demonstrated to be the best predictors of hyperglycaemia [47], hypertriglyceridemia [47] and HOMA-IR [69] together with waist circumference, in patients with hypoprolactinemia. The gene discussed is PRL; the disease is hypertriglyceridemia.